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ACROMEGALY: 
 
TREATMENT & MANAGEMENT  
 
MEGHA TILVAWALA 
 
ABSTRACT 
 Acromegaly is a multi-system disorder whose etiology is most often 
traced back to a growth hormone-secreting pituitary adenoma (PA). Growth 
hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release 
from peripheral tissues, leading to the clinical manifestations of acromegaly. 
Current treatment methods for acromegaly include surgery, medical therapy, 
and radiation therapy. The goals of acromegaly treatment are to reduce GH 
levels and IGF-1 levels to age/sex-normalized levels, relieve comorbidities, 
normalize mortality rate, and to remove the pituitary mass causing high 
hormone levels. This study aims to provide a comprehensive review of current 
treatment methods and an analysis of novel therapies for treatment of 
acromegaly. 
 The primary treatment method of acromegaly is surgery due to limited 
complications, relatively low cost, and remission in the majority of cases. 
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However, surgery is not an effective treatment method for invasive 
macroadenomas with extension into the intracranial space. Medical therapies 
such as dopamine agonists (DAs) and somatostatin receptor ligands (SRLs) are 
effective at reducing GH and IGF-1 levels and may have anti-tumor effects. 
However, DAs are only effective at treating minor elevations in GH and IGF-1 
levels and SRLs may cause hyperglycemia after prolonged treatment. In contrast 
to DAs and SRLs, Pegvisomant does not have anti-tumor effects, but it is more 
effective at reducing GH and IGF-1 levels. The disadvantages of Pegvisomant are 
the possibility of irreversible liver damage and the overwhelming cost of 
treatment. Stereotactic radiosurgery (SRS) is another mode of treatment for 
acromegaly, however, there are many disadvantages to SRS including prolonged 
latency period, hypopituitarism, radio-necrosis of normal brain tissue, and 
secondary tumor formation. Novel therapies for acromegaly include antisense 
drugs and modified botulin neurotoxins. Despite the success of antisense drugs 
and modified botulin neurotoxins in animal models, greater research is required 
prior to application in human clinical trials. Gene therapy is an emerging 
treatment method for acromegaly and proper manipulation of viral 
immunogenic effects could prove as a successful treatment for large 
macroadenomas, invasive PAs, and recurrent PAs. 
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 Despite the success of surgery in treating microadenomas and 
noninvasive macroadenomas, therapeutic alternatives must be explored to treat 
invasive PAs, macroadenomas, and recurrent PAs. Future research in 
immunotherapies and gene therapies may provide greater insight into the 
development of more effective and less invasive treatment methods for 
acromegaly. 
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INTRODUCTION 
 
Acromegaly is a multisystem disorder whose etiology is most often traced 
back to supraphysiological levels of growth hormone (GH) secreted by a benign, 
pituitary adenoma (PA) (Annamaria Colao, Ferone, Marzullo, & Lombardi, 
2004). GH promotes synthesis and secretion of insulin-like growth factor I (IGF-
1) from peripheral tissues. Chronic exposure to elevated GH and IGF-1 levels 
leads to systemic complications seen in acromegaly including rheumatological, 
cardiovascular, respiratory, metabolic, and endocrine dysfunctions. Acromegaly 
patients present with significant morbidity and increased mortality due to these 
complications. The current treatment for acromegaly includes medical therapy, 
radiation therapy, and surgical resection (Capatina & Wass, 2015).  
 
Epidemiology 
Pituitary tumors are the second most common type of primary 
intracranial tumors, exceeded in frequency only by meningiomas. Pituitary 
tumors account for approximately 16.5% of all primary brain tumors and 23.8% 
of non-malignant primary brain tumors. The overall incidence rate of pituitary 
tumors is 3.94 cases per 100,000 individuals with greater incidence in females 
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than males. The median age of incidence is 51 (Ostrom et al., 2018). Between ages 
55 and 85, the incidence of pituitary tumors is greater in men than in women. A 
reason for the higher incidence in pituitary tumors in men later in life may be 
due to the clinical manifestations of pituitary tumors. For example, amenorrhea 
or menstrual dysfunction caused by a secretory pituitary tumor may be 
misdiagnosed for menopause in women, decreasing the diagnosis of pituitary 
tumors in older women. This could be the reason why there are more diagnoses 
of women with a pituitary tumor earlier in life while a greater number of men 
are diagnosed later in life (Linda Bi, Smith, Nery, Dunn, & Laws, 2016; McDowell 
et al., 2011). 
Acromegaly is a relatively rare disorder that has an estimated annual 
incidence of three to four cases per million population. It affects men and women 
with approximately similar frequency (Annamaria Colao et al., 2004). Due to the 
disease’s slow progression and indolent behavior, diagnosis of acromegaly can 
be delayed for 2-3 years after disease onset. Early diagnosis is crucial for patients 
due to disease-associated comorbidities that increase morbidity and mortality. 
Increased mortality rates in acromegalic patients are often associated with 
dilated cardiomyopathy and conduction disorders that arise from chronic, 
elevated plasma GH and IGF-1 levels. Therefore, early diagnosis is essential to 
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decrease mortality rates that can be two to four times greater in acromegaly 
patients than in the general population. (Nachtigall et al., 2008). 
 
Pituitary Gland Structure, Function, Embryology 
The pituitary gland is an important neuro-endocrine structure that 
regulates hormonal signals for adrenal function, thyroid function, reproduction, 
growth, and metabolism, as well as osmoregulation. It secretes trophic hormones 
in response to hypothalamic, intra-pituitary, and peripheral factors (Shlomo 
Melmed, 2006). The pituitary gland is a fused, bilobed structure that consists of 
three distinct regions: the anterior pituitary (adenohypophysis), the posterior 
pituitary (neurohypophysis), and the pars intermedia. Each region is distinct in 
terms of its morphology, origin, and hormonal secretions. The posterior pituitary 
gland (neurohypophysis) is an extension of gray brain matter that rests within 
the sella turcica of the sphenoid bone at the cranial base. It is directly attached to 
the hypothalamus via the infundibulum (Linda Bi et al., 2016). Similar to other 
central nervous system structures, the pituitary gland is covered by dura mater: a 
dense, protective, irregular connective tissue that surrounds the brain and spine. 
A small aperture within the dura allows passage of the infundibulum from the 
hypothalamus to the sella and also stabilizes the pituitary gland superiorly. The 
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pituitary gland is bounded laterally by the cavernous sinus, anteriorly bound by 
the sphenoid sinus, and inferiorly bound by the clivus (Figure 1). Complications 
may arise when pituitary adenomas (PAs) stretch and erode through the 
aperture in the dura to invade the intracranial compartment surrounding 
essential structures such as the internal carotid artery and optic chiasm (Larkin & 
Ansorge, 2000).  
 
 
Figure 1 – Coronal Section Describing Anatomy of Sella. The pituitary gland is 
laterally covered by the cavernous sinus which contains trabeculated venous 
spaces to allow passage of cranial nerves and the internal carotid artery. The 
contents of the cavernous sinus include: cranial nerve III (oculomotor nerve), IV 
(trochlear nerve), V (trigeminal nerve divisions V1 and V2), and VI (abducens 
nerve). The optic chiasm also rests in close proximity to the pituitary gland 
(Linda Bi et al., 2016). 
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The adenohypophysis is derived from epithelial cells of the primitive 
digestive tract. It has glandular structure that is composed of five distinct cell 
types: somatotrophs, lactotrophs, corticotrophs, thyrotrophs, and gonadotrophs. 
Approximately 50% of all cells in the adenohypophysis are somatotrophs that 
synthesize GH, 10-25% are lactotrophs that synthesize prolactin (PRL), 15-20% 
are corticotrophs that synthesize adrenocorticotropic hormone (ACTH), 10-15% 
are gonadotrophs that synthesize luteinizing hormone and follicle-stimulating 
hormone (LH and FSH), and the remaining 3-5% of cells are thyrotrophs that 
synthesize thyroid-stimulating hormone (TSH) (Table 1). The adenohypophysis 
is vascularized by the superior hypophyseal artery, the premamillary artery, and 
branches of the posterior communicating artery (Nussey & Whitehead, 2001). 
 
Table 1 – Adenohypophysis Cell Types and Concentrations. This table 
summarizes the various cell types in the anterior pituitary with their associated 
concentrations and secretory products (Nussey & Whitehead, 2001). 
Cell Type Concentration of Cells in Anterior Pituitary (%) Secretory Product 
Somatotrophs 50% Growth Hormone 
Lactotrophs 10-25% Prolactin 
Corticotrophs 15-20% 
Adrenocorticotropic 
Hormone 
Gonadotrophs 10-25% 
Luteinizing Hormone & 
Follicle-Stimulating 
Hormone 
Thyrotrophs 3-5% Thyroid-stimulating 
Hormone 
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The adenohypophysis expresses distinct regionalization of cell types that 
form clusters in preferential locations. Somatotrophs and lactotrophs that 
produce GH and PRL, respectively, are bilateral to a central, trapezoidal ACTH 
and TSH-secreting section (Figure 2). The majority of the GH-producing cells line 
the anterior surface of the adenohypophysis and are where the majority of 
somatotroph PAs arise (Linda Bi et al., 2016). 
 
 
Figure 2 – Distribution of Cell Types within the Anterior Pituitary. The 
horizontal section of the adenohypophysis depicts the distribution of various cell 
types. The GH-producing cells reside on the lateral edges and are separated by a 
central, trapezoid of ACTH and TSH-secreting cells. Somatotroph PAs arise from 
the GH-secreting region of the adenohypophysis. Due to the close proximity of 
somatotrophs to lactotrophs, some PAs co-secrete PRL alongside GH (Linda Bi et 
al., 2016). 
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GH is a single-chain polypeptide that is secreted in pulsatile fashion under 
the control of stimulatory and inhibitory hypothalamic hormones that circulate 
through the hypophyseal portal system. Pulses of GH secretion are interspersed 
with minimal, basal secretion that is dependent on age, sex, nutrition, 
neurotransmitters, exercise, and stress levels of the patient (Linda Bi et al., 2016; 
Shlomo Melmed, 2009). Hypothalamic growth hormone-releasing hormone 
(GHRH) and ghrelin, a gastrointestinal hormone, stimulate the synthesis and 
release of GH. Binding of GHRH and ghrelin to transmembrane G protein-
coupled receptors (GPCRs), activates an intracellular cascade that promotes 
secretion of transcription factors: paired-like homeodomain factor 1 and POU 
class 1 homeobox 1 (POU1F1). These transcription factors mediate synthesis and 
secretion of GH from somatotrophs and cell proliferation. The release of GH 
stimulates peripheral IGF-1 release, mainly from the liver and cartilage among 
other tissues, to promote cell proliferation and inhibit apoptosis. In contrast, 
binding of hypothalamic somatostatin to transmembrane GPCRs promotes an 
intracellular cascade that inhibits the secretion of GH (Figure 3). In a normal, 
physiological state, elevated serum IGF-1 provides negative feedback onto 
somatotrophs to also inhibit secretion of GH (Shlomo Melmed, 2006).  
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Figure 3 – Control of GH Secretion in Adenohypophysis. GHRH, GH, and 
somatostatin (SRIF) traverse the pituitary portal system and bind to receptors 
throughout the adenohypophysis. GHRH from the hypothalamus and ghrelin 
from the gastrointestinal tract stimulate GH secretion. GHRH can also act as an 
agonist on the ghrelin receptor to stimulate GH secretion. Upon binding of 
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GHRH to the transmembrane GPCR, an intracellular cascade induces activation 
of transcription factor POU1F1 that promotes GH gene transcription, translation, 
and secretion. Somatostatin (SRIF) binding to the transmembrane GPCR at SSTR-
2 and SSTR-5 promotes an intracellular cascade that inhibits GH secretion from 
somatotrophs. Normal GH secretion proceeds in pulsatile fashion with greater 
secretion at night in comparison to the day time. In acromegaly, GH secretion is 
elevated and is secreted at much higher levels than normal physiological levels 
(Shlomo Melmed, 2009). 
 
 
Clinical and Pathological Features of Acromegaly 
The clinical manifestations of acromegaly arise in response to excess GH 
levels that subsequently lead to high plasma IGF-1 levels. In more than 95% of 
patients, acromegaly is the result of a benign, GH-secreting PA that arises after 
puberty. If the GH-secreting PA arises prior to epiphyseal closure at puberty, GH 
and IGF-1 excess leads to gigantism (Linda Bi et al., 2016). Acromegaly affects all 
body systems due to the widespread action of IGF-1. The most common clinical 
manifestations of acromegaly include acral and soft tissue overgrowth, skin 
thickening, macrognathia (abnormally large jaw), enlarged/swollen hands and 
feet, increase in shoe size, and an increase in ring size (M. E. Molitch, 1992). 
Other clinical manifestations and subsequent comorbidities of acromegaly are 
listed in Table 2. In approximately 30% of cases, patients also present with 
elevated PRL levels in response to either a mixed GH and PRL secreting PA or 
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mass effect of the tumor on the pituitary stalk. This latter phenomenon is 
referred to as “stalk effect” and is caused by compressive lesions that impinge on 
the pituitary stalk or hypothalamus. In a normal setting, PRL secretion is 
inhibited by tonic release of hypothalamic dopamine. Lesions that impair the 
release of dopamine or the transfer of dopamine from the hypothalamus to the 
anterior pituitary cause disinhibition of PRL release, which leads to moderately 
elevated PRL levels (Linda Bi et al., 2016). In rare cases, some tumors may co-
secrete TSH or ACTH alongside GH. PAs are classified into three groups based 
on tumor size: microadenomas (<10 millimeters), macroadenomas (>10 
millimeters), and giant PAs (>4 centimeters) (Shlomo Melmed, 2009). 
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Table 2 – Clinical Manifestations and Comorbidities of Acromegaly. Summary 
of the multi-system effects of chronic, supraphysiological levels of GH and IGF-1 
in response to a GH-secreting PA. (Capatina & Wass, 2015). 
 
 Skin Thick, oily skin 
Hyperhidrosis 
Skin tags 
Acanthosis nigricans 
Musculoskeletal System Somatic changes (prognathism, frontal 
bossing, acral enlargement) 
Arthralgias, osteoarthritis 
Chronic pain 
Hearing loss 
Myopathy 
Decreased bone quality, vertebral fractures 
Cardiovascular Arterial hypertension 
Cardiomyopathy 
Ventricular hypertrophy 
Arrhythmias 
Congestive heart failure 
Metabolic Diabetes mellitus 
Glucose intolerance 
Gastrointestinal Colon polyps 
Dental changes (separation; jaw malocclusion) 
Respiratory System Sleep apnea 
Upper airway obstruction 
Macroglossia 
Visceromegaly Goiter 
Macroglossia 
Cardiomegaly 
Hepatomegaly 
Splenomegaly 
Neurological Carpal tunnel syndrome 
Cerebral aneurysms 
Headache 
Local Tumor Effects Visual field deficits, cranial nerve palsy 
Headache 
Hypopituitarism 
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Retrospective studies of acromegaly patients revealed a 10-year reduction 
in life expectancy and doubling of the standardized mortality rate due to 
cardiovascular, cerebrovascular, metabolic, and respiratory comorbidities 
(Shlomo Melmed, 2009). Cardiovascular complications arise in one-third of 
acromegaly patients and include cardiac hypertrophy, congestive heart failure, 
hypertension, obstructive sleep apnea, and arrhythmias (Sharma, Nguyen, 
Brown, & Robbins, 2017). However, aggressive reduction and control of 
circulating IGF-1 and GH levels to less than 2.5µg/L may reverse acromegaly-
related hypertension. This subsequently decreases standardized mortality rates 
to match those of the standard population (Murray & Melmed, 2008; Sharma et 
al., 2017).  
 
Diagnosis 
Diagnosis of acromegaly is generally made in accordance with elevated 
IGF-1 levels, not GH levels. This is because GH is released in pulsatile fashion 
with periods of low levels of secretion and spikes of high levels of secretion. 
Therefore, a random reading of “elevated” GH may correspond to normal, peak 
GH secretion in a non-acromegalic patient (Sata & Ho, 2007). Patients that 
present with the typical clinical manifestations of acromegaly, especially acral 
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and facial feature changes, are likely to have acromegaly and should have IGF-1 
levels measured. Some patients do not present with morphometric 
manifestations, but may have several of the associated conditions including sleep 
apnea syndrome, type II diabetes mellitus, debilitating arthritis, carpal tunnel 
syndrome, hyperhidrosis, and hypertension. Due to the high risk of these 
comorbidities, IGF-1 levels should also be measured in these cases to test for 
acromegaly. Patients that present with a pituitary mass should also have IGF-1 
measured to rule out acromegaly. In some cases, patients may have equivocal 
IGF-1 levels, which require a confirmation of diagnosis by an oral glucose 
tolerance test (OGTT). In an OGTT, GH levels are measured over an allotted time 
period after a documented hyperglycemic event to determine GH response to 
elevated glucose levels. The failure of GH suppression after an OGTT suggests 
diagnosis of acromegaly.  
Once a patient is diagnosed with acromegaly, imaging studies are utilized 
to visualize and evaluate tumor size, location, and extent of parasellar invasion. 
Magnetic resonance imaging (MRI) is favored in comparison to a computerized 
tomography (CT) scan due to a superior range in soft tissue contrast, greater 
detail, and increased sensitivity and specificity for brain abnormalities. Visual 
field testing would also be performed if the tumor appears to compress the optic 
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chiasm to monitor the patient before and after treatment. The appropriate 
treatment method is decided after thorough evaluation of all comorbidities and 
tumor characteristics (Katznelson et al., 2014; Sata & Ho, 2007). 
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Specific Aims 
1. Comprehensive review of current data and information regarding the 
pathogenesis and clinical presentation of acromegaly. 
2. Report of the current treatment methods for acromegaly, including 
therapy effectiveness, mode of action, and availability to patients. 
3. Analysis of novel therapies to treat acromegaly, including therapy 
effectiveness and mode of action. 
4. Conclusion on which therapies appear to work and have the most promise 
as therapies for acromegaly. 
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PUBLISHED STUDIES 
 
 There are several treatment options for management of acromegaly 
including medical therapy, surgical resection, and radiation therapy. The goals of 
acromegaly treatment are to reduce GH and normalize IGF-1 levels to the 
age/sex-adjusted range, alleviate comorbidities, normalize mortality rate, and to 
reduce or eliminate the pituitary tumor mass (Mark E. Molitch, 2017).  
 
Surgery 
For most acromegaly patients, surgery is the initial treatment modality. 
The goals of pituitary surgery are to relieve mass effect (compression of optic 
chiasm or impinged pituitary stalk), achieve biochemical control (normal GH 
levels, age/sex-normalized IGF-1 levels), preserve or restore pituitary function, 
minimize risk of tumor recurrence, and confirm a histopathologic diagnosis 
(Linda Bi et al., 2016). In rare emergent cases, patients may present with pituitary 
apoplexy, an infarction or acute hemorrhage of the pituitary gland. Pituitary 
apoplexy is described as the manifestation of headaches, visual loss, decreased 
consciousness, nausea, vomiting, or altered mental state in response to a vascular 
condition within the sellar compartment. Untreated apoplexy can lead to 
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permanent hypopituitarism, which can be lethal due to acute adrenal 
insufficiency. Therefore, surgical resection may be utilized to relieve symptoms 
resulting from acute mass effect of pituitary apoplexy and preserve pituitary, as 
well as visual, function. (Briet, Salenave, Bonneville, Laws, & Chanson, 2015).  
The efficacy of surgery depends on factors including tumor size, 
invasiveness of the tumor, preoperative GH levels, and the experience level of 
the surgeon (Mark E. Molitch, 2017). In the most ideal case, resection of a 
noninvasive, intrasellar, GH-secreting microadenoma with basal preoperative 
GH levels may lead to complete remission. In contrast, resection of invasive, GH-
secreting macroadenomas with excessively high preoperative GH levels may 
prove unsuccessful due to the inability to remove the entire tumor. Most 
pituitary surgeries are conducted using an endonasal transsphenoidal approach 
with minimally invasive endoscopic techniques. Endoscopic endonasal 
transsphenoidal pituitary surgery minimizes postoperative discomfort, provides 
superior visualization of anatomical structures, and lessens the difficulty 
associated with reoperation (Campbell et al., 2010) (Figure 4). Novel advances 
such as computerized image guidance, intraoperative MRI, micro-
instrumentation and optics have led to safe, effective, and minimally traumatic 
surgical experiences. For pituitary tumors with extrasellar extension into the 
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cavernous sinus, a transcranial approach may be favored. This approach is used 
less frequently, however, it allows the surgeon a more holistic view of the 
tumor’s effect on intracranial structures such as the optic nerves and chiasm 
(Linda Bi et al., 2016). GH-secreting tumors have a high likelihood of invading 
laterally into the cavernous sinus, thereby increasing the risks associated with 
surgical resection. Therefore, great care must be taken by the surgeon during 
surgical resection due to the close proximity of important neural and vascular 
structures, such as the optic chiasm and the internal carotid artery (Shlomo 
Melmed, 2009).  
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Figure 4 – Endoscopic Transnasal Transsphenoidal Surgical Approach. 
Transnasal transsphenoidal endoscopic surgery is divided into three major 
phases: nasal, sphenoidal, and sellar. In the nasal phase, an endoscope is used 
with the aid of a vasoconstrictive agent to identify the sphenoid ostia. During the 
sphenoidal phase, the sphenoid sinus will be entered to reveal the sellar floor. In 
the sellar phase, an incision is made into the bony sellar floor to reveal the dura 
mater that encases the pituitary gland. An incision is made in the dura mater to 
allow access to the pituitary tumor. Inferior and lateral portions of the pituitary 
tumor are removed first, which allows the superior portion to descend for 
removal (“Endoscopic transnasal transsphenoidal surgery,” n.d.; Linda Bi et al., 
2016).  
 
In a retrospective review of 26 patients undergoing a purely endoscopic 
transsphenoidal resection of GH-secreting PA, 57.7% of patients achieved 
biochemical control (age-appropriate IGF-1 levels, GH levels <2.5 µg/L, GH levels 
< 1ng/mL, nadir GH level after oral glucose load of <1 µg/L) (Campbell et al., 
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2010). In another study analyzing the efficacy of endoscopic transsphenoidal 
surgery in 401 patients, a total surgical resection was performed in 77.56% of 
patients. Remission (age/sex-normalized IGF-1 levels) was achieved in 68.1% of 
patients: 81.3% of patients with microadenomas, 63.3% of patients with 
macroadenomas, and 40.7% of patients with cavernous sinus invasion (Anik et 
al., 2017). Another study identified remission in 64% of patients that underwent 
surgical resection of a macroadenoma (I. Shimon, Cohen, Ram, & Hadani, 2001). 
It should be noted that the percent of patients in remission in each study is 
dependent on the accepted IGF-1 and GH levels that are used to define disease 
cure. 
Large macroadenomas (>20 millimeters) and preoperative GH levels that 
are greater than 5 µg/L have poor prognosis with surgical resection, and require 
adjuvant therapy to control elevated GH levels (I. Shimon et al., 2001). More than 
65% of GH-secreting tumors are diagnosed as invasive macroadenomas. In these 
cases, surgical outcomes are less favorable and there is a greater likelihood of 
elevated postoperative GH levels due to the inability to remove the entire tumor. 
Giant GH-secreting PAs (> 4 centimeters) present with extrasellar extension, 
chiasmal compression, cavernous sinus invasion, and occasionally involve other 
cranial structures such as the hypothalamus, clivus, or temporal lobe. For 
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patients with giant PAs, surgical debulking may relieve certain side effects such 
as chiasmal compression. It may also make tumors more responsive to other 
therapies. Although, there is a small likelihood that these patients will never 
achieve remission as extrasellar invasion makes total resection of tumor unlikely 
(Ilan Shimon et al., 2015). Patients that have undergone total resection of a PA 
may have tumor recurrence. Recurrence rates for PAs vary between studies due 
to the stringency of the criteria by which remission is defined and the length of 
patient follow-up. One study approximated the recurrence rate for GH-secreting 
PAs to be 6% for patients treated with transsphenoidal surgery for total resection 
of a PA (Fernández Mateos, García-Uria, Morante, & García-Uría, 2017). These 
patients are candidates for reoperation or treatment through other methods. For 
acromegaly patients with recurrent PAs, a 48% rate of secondary remission was 
observed after reoperation (Linda Bi et al., 2016). 
The complications of pituitary surgery include, cerebrospinal fluid leaks, 
local hemorrhage due to vascular injury, sinonasal (obstruction, sinus infection, 
hyposmia), visual compromise, pituitary dysfunction, hypothalamic injury, 
diabetes insipidus, and local infection (Linda Bi et al., 2016; Shlomo Melmed, 
2009). In the aforementioned study conducted by Anik et al., 18.45% of patients 
experienced complications. 11.22% of patients experienced endocrinologic 
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complications including temporary diabetes insipidus (3%), hypogonadism (3%), 
pituitary insufficiency (1.75%), hypothyroidism (1.75%), adrenal insufficiency 
(1.4%) and permanent diabetes insipidus (0.2%). 7.23% of patients experienced 
anatomic complications including cerebrospinal fluid (CSF) leaks (2.7%), 
epistaxis (8%), sellar hematoma (1.24%), cranial nerve injury (0.75%), sphenoid 
sinusitis (0.2%), and meningitis (0.2%) (Anik et al., 2017). However, another 
study reported a lower complication rate at 11.5% following endoscopic 
transsphenoidal surgery (Campbell et al., 2010). Some acromegaly patients 
present with respiratory and cardiovascular comorbidities that may require 
specialized perioperative medical management. Soft tissue hypertrophy and 
bony alterations in acromegaly cause abnormal airway anatomy that make 
intubation a difficult task intraoperatively. Therefore, endoscopic 
transsphenoidal surgical resection of PAs must be conducted after a complete 
evaluation of the patient’s condition and appropriate preparedness by operating 
room staff to prevent complications perioperatively and postoperatively (Friedel 
et al., 2013). 
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Medical Therapy 
Medical therapy is used as a primary treatment for acromegaly patients 
who are unable to have surgery and patients that decline surgery. Medical 
therapy may also be used preoperatively for patients with pituitary tumors that 
invade neurovascular structures or as treatment after partial surgical resection of 
a PA. Currently, there are three medical therapies used for management of 
acromegaly: dopamine agonists, somatostatin receptor ligands, and growth 
hormone receptor antagonists (Table 3) (Kumar, Ayuk, & Murray, 2009). 
 
Dopamine Agonists 
Physiologically, in non-acromegalic patients, dopamine stimulates GH 
secretion from somatotrophs by binding to the dopamine D2 receptor on the 
anterior pituitary. Most GH-secreting PAs also primarily express the dopamine 
D2 receptor. However, upon administration of a dopamine agonist (DA) to 
acromegalic patients, an unexpected fall in plasma GH levels is observed 
(Chiodini, Liuzzi, Botalla, Cremascoli, & Silvestrini, 1974). This phenomenon is 
not well understood, however, this property of D2 receptor activity has been 
manipulated for treatment of acromegaly. Clinically available DAs include 
bromocriptine, cabergoline, and quinagolide.  
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Bromocriptine has been used for treatment of acromegaly for more than 
20 years. However, only 50% of patients experience a decrease in symptoms or 
disease severity; 20% of patients achieve GH levels < 5µg/L, and 10% of patients 
achieve normalization of IGF-1 levels (S. Melmed, Ho, Klibanski, Reichlin, & 
Thorner, 1995). More recently, cabergoline, the preferred medical therapy for 
treatment of hyperprolactinemia, has been used off-label for treatment of 
acromegaly. Studies indicate that cabergoline is more effective, longer-acting, 
and a better tolerated medication than bromocriptine. Cabergoline monotherapy 
in 149 patients decreased GH levels to <2.5 µg/L in 48% of patients and decreased 
IGF-1 levels to age-normalized values in 34% of patients. In other studies, 
cabergoline also led to tumor shrinkage in one-third of patients. Although, tumor 
shrinkage was linked to higher basal PRL and IGF-1 levels, and only presented in 
patients that had previously undergone treatment (Kuhn & Chanson, 2017). 
Another DA, quinagolide, normalized GH and IGF-1 levels in 47.8% of 
acromegalic patients suggesting that it may be a more effective medical therapy 
in comparison to cabergoline and bromocriptine (Annamaria Colao et al., 2001). 
However, quinagolide and bromocriptine cause adverse effects including 
nausea, headache, dizziness, and hypotension, whereas cabergoline is well-
tolerated in patients (Annamaria Colao et al., 1997). Therefore, cabergoline is a 
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medical therapy that may be used to achieve normal GH and IGF-1 levels in 
patients with relatively mild elevations of these hormones (Kuhn & Chanson, 
2017; Mark E. Molitch, 2017). 
 
Somatostatin Receptor Ligands 
Physiologically, somatostatin is effective at reducing GH secretion in the 
adenohypophysis by binding to any of the five somatostatin receptors (SSTRs). 
GH-secreting PAs heterogeneously express four of the five SSTRs (SSTR-2 > 
SSTR-5 > SSTR-1 > SSTR-3) with evidence suggesting a functional link between 
SSTR-2 and SSTR-5 receptor. Therefore, somatostatin receptor ligands (SRLs) that 
activate both SSTR-2 and SSTR-5 receptors may be more effective at reducing GH 
secretion in comparison to analogs that only activate one of the five receptors 
(Greenman & Melmed, 1994; Shlomo Melmed, 2009). Clinically available SRLs 
include the long-acting formulations of octreotide, lanreotide and pasireotide. 
SRLs are the first medical therapy of choice for acromegaly when surgical 
success is not feasible. SRLs may also be used as the second line of therapy when 
a subtotal resection of a GH-secreting PA results in persistently elevated GH and 
IGF-1 levels postoperatively. SRLs are also used immediately following radiation 
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therapy to provide treatment during the radiotherapy latency period (Marko, 
LaSota, Hamrahian, & Weil, 2012). 
 
First-Generation SRLs 
Both octreotide and lanreotide exhibit longer half-lives than native 
somatostatin which is only active for 2 minutes in physiological conditions 
(Shlomo Melmed et al., 2015). The commonly used form of octreotide is 
octreotide long-acting release (octreotide LAR) which is a microsphere 
preparation that is injected intramuscularly every four to six weeks. The 
commonly used form of lanreotide is Lanreotide Autogel (lanreotide ATG) 
which is a water-soluble formulation that is injected subcutaneously every four 
to six weeks. Octreotide and lanreotide exhibit high affinity binding to the SSTR-
2 receptor with moderate binding affinity to the SSTR-5 receptor (Kumar et al., 
2009). 
Octreotide LAR can be utilized as a primary therapy in the case of small, 
GH-secreting microadenomas with preliminary circulating GH levels that are 
less than 20 µg/L. In response to primary therapy of octreotide LAR, 29% of 
patients had GH levels less than 2µg/L, age-normalized IGF-1 levels, and greater 
than 30% shrinkage of the tumor (Bevan et al., 2002; Murray & Melmed, 2008). In 
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another study, GH level reduction and IGF-1 level reduction was seen in 69.2% 
and 73.7% of patients, respectively, in response to long-term primary or 
secondary octreotide therapy (Annamaria Colao et al., 2001). Lanreotide exhibits 
similar activity to octreotide. Lanreotide slow-release (lanreotide SR), a form of 
lanreotide that is similar in efficacy to lanreotide ATG, reduces GH and IGF-1 
levels after a two-year treatment period. In de novo patients, lanreotide SR 
induces disease control in 70% of patients and causes tumor shrinkage in 22% of 
patients (Baldelli et al., 2000). Another study reports that lanreotide causes GH 
levels to fall below 2.5 µg/L and age-normalized IGF-1 levels in 45% of patients 
and 44% of patients, respectively (Verhelst et al., 2000).  
Both octreotide and lanreotide are effective primary therapies for large or 
invasive tumors where surgical cure is low and vision or neurological function is 
not threatened (Newman et al., 1998). More specifically, 3-month treatment of 
lanreotide prior to surgical resection decreased tumor volume, tumor invasion, 
postoperative GH and IGF-1 levels, and improved surgical cure rates in patients 
with invasive macroadenomas. The 16-week cure rate in pre-treated lanreotide 
patients was 49% whereas patients that underwent surgery without primary 
therapy of lanreotide only had an 18.4% cure rate (Li, Quan, Tian, & Cheng, 
2012). Octreotide may also be used as secondary or tertiary treatment methods. 
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In patients with severe acromegaly where surgery alone is not curative, 
octreotide LAR may be utilized as a secondary therapy after surgical debulking 
of the PA to gain biochemical control in patients. Surgical debulking increases 
the efficacy of secondary octreotide treatment (Fahlbusch et al., 2017). Octreotide 
is more effective at reducing GH and IGF-1 levels than lanreotide when used as a 
secondary or tertiary treatment method (Marko et al., 2012). Common side effects 
of octreotide and lanreotide treatment include gallbladder stones and sludge, 
abdominal cramps, flatulence, and diarrhea (Dowling, Hussaini, Murphy, Besser, 
& Wass, 1992; Mark E. Molitch, 2017). 
 
Second-Generation Somatostatin Receptor Ligand 
Pasireotide long-acting release (pasireotide LAR), a second-generation 
SRL, exhibits unique properties that allow it to bind to all four SSTRs present in 
PAs with preferential binding to SSTR-5. In a phase III trial examining the 
efficacy of pasireotide LAR versus octreotide LAR in 358 treatment naïve 
patients, 31.3% of patients achieved biochemical control (GH levels <2.5 µg/L and 
IGF-1 normalized for age and sex) in the pasireotide LAR group in comparison to 
19.2% of the octreotide LAR group. Mean tumor volume reduction between both 
groups was 40% (A. Colao et al., 2014). In another randomized, phase III trial, 
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pasireotide treatment was compared to octreotide or lanreotide treatment in 198 
patients. Acromegaly patients were either given 60 mg of pasireotide, 40 mg of 
pasireotide, or continued treatment with either lanreotide or octreotide (active 
control). After 24 weeks, 15% of patients in the 40 mg pasireotide group and 20% 
of patients in the 60 mg pasireotide group achieved biochemical control (GH <2.5 
µg/L and IGF-1 normalized for age and sex) in comparison to 0% of patients in 
the active control group (Gadelha et al., 2014). These studies confirmed 
biochemical control of acromegaly at higher rates than previously seen in first-
generation SRLs. Due to the effectiveness of pasireotide, it may specifically be 
used for treatment in patients that do not respond to first-generation SRLs 
(Capatina & Wass, 2015). The most common side effect of pasireotide treatment 
is hyperglycemia which was observed in 31-57% of patients in various studies. 
Hyperglycemia was managed and responsive to antidiabetic medication such as 
metformin, insulin, or glimepiride (Gadelha et al., 2014). 
 
Growth Hormone Receptor Antagonists 
Another medical therapy for treatment of acromegaly are growth 
hormone receptor antagonists (GHRAs). GHRAs bind to peripheral targets to 
prevent GH action and subsequent IGF-1 secretion. Pegvisomant is a competitive 
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GH antagonist that binds the GH receptor and inhibits receptor conformational 
changes that are necessary for signaling. Pegvisomant decreases circulating IGF-
1 levels, however, circulating GH levels increase with treatment due to the lack 
of IGF-1 negative feedback on somatotrophs (Shlomo Melmed, 2009).  
In a randomized, double-blind study, patients were given a placebo, 10 
mg of Pegvisomant, 15 mg of Pegvisomant, or 20 mg of Pegvisomant per day. 
IGF-1 concentrations reduced to the age-normalized concentrations in 10% of the 
placebo patients, 54% of the patients taking 10 mg of Pegvisomant, 81% of the 
patients taking 15 mg of Pegvisomant, and 89% of the patients taking 20 mg of 
Pegvisomant. Patients that took Pegvisomant had significant decreases in IGF-1 
levels with minimal adverse effects, suggesting that Pegvisomant alone could 
serve as a potential treatment for acromegaly (Trainer et al., 2009). Many patients 
also noted an improvement in symptoms associated with acromegaly such as 
fatigue, headache, arthralgias, edema, excessive perspiration, and ring size 
(Tritos & Biller, 2017). However, it should be noted that Pegvisomant does not 
have anti-tumor growth effects. Patients treated with Pegvisomant required 
serial imaging of the tumor every 6 months until no change is observed in tumor 
growth after which serial imaging is suggested yearly (Katznelson et al., 2014). 
The side effects of Pegvisomant include irreversible elevation of liver 
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transaminases, injection site reactions, lipohypertrophy in response to local 
adipocyte insensitivity, and possible continued tumor growth. In the German 
Pegvisomant Observational Study, 9% of patients presented with elevated liver 
transaminases that were greater than 3 times the normal levels after which 
treatment is halted (Schreiber et al., 2007).  
 
Radiation Therapy 
Even though most GH-secreting PAs are benign, many may be refractory 
to medical and surgical interventions. For this reason, radiation therapy (RT) is 
utilized as adjuvant therapy in treatment of residual tumors with persistent 
hormone secretion that invade neurovascular structures, and recurrent tumors. 
The effectiveness of RT is dependent on tumor size with diminishing effects on 
larger tumor masses (Linda Bi et al., 2016). There are 2 types of RT: conventional 
external beam RT and stereotactic radiosurgery (SRS). Conventional RT is a 
cumulative radiation dose that is divided over many treatments until the total 
dose is met. In comparison to conventional radiotherapy, SRS utilizes relatively 
narrow beams of g radiation to administer a high dose of radiation with 
stereotactic precision to tumors that are distant from the optic tract (Shlomo 
Melmed, 2009). SRS is a single dose that can be administered using gamma knife-
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emitting sources (Gamma-Knife), using linear accelerator (LINAC). SRS may also 
be delivered as multiple doses via fractionated stereotactic radiotherapy (FSRT) 
(Giuseppe Minniti, Scaringi, & Enrici, 2011).  
Conventional RT reduced GH levels to less than 2µg/L and age-
normalized IGF-1 levels over the span of ten years in over 50% of patients 
(Jenkins, Bates, Carson, Stewart, & Wass, 2006). A series of other studies 
indicated that tumor control and normalization of IGF-1 and GH levels was 
reached in 80-90% of patients and 50-60% of patients, respectively (Giuseppe 
Minniti et al., 2011). Despite the success associated with conventional RT, there 
are many reports of adverse effects which include hypopituitarism, visual loss or 
deterioration, brain radio-necrosis, secondary tumor formation, and 
neuropsychological damage. Ten years after radiation treatment, 58%, 50%, and 
44% of patients were deficient in LH/FSH, ACTH, and TSH, respectively. Only 
60% of patients had an intact hypothalamic-pituitary axis (Jenkins et al., 2006). 
There is an actuarial incidence of 2.4% risk at 20 years for development of a 
secondary tumor in response to conventional RT (G. Minniti, Traish, Ashley, 
Gonsalves, & Brada, 2005). In addition, there is also concern of toxicity associated 
with long-term exposure to RT (Giuseppe Minniti et al., 2011). 
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Stereotactic radiosurgery (SRS) is recommended for treatment of tumors 
that are smaller than 3 centimeters and greater than 3 to 4 millimeters from the 
optic chiasm. The optic chiasm has a maximum tolerance of 10 Gy for SRS, but if 
the tumor is within 3 to 4 millimeters of the optic chiasm, FSRT may be utilized 
to reduce detrimental effects. On average, patients achieve remission after 3.3 
years (Marko et al., 2012). In comparison to conventional RT, SRS studies 
reported lower rates of hypopituitarism and other adverse effects of 
conventional RT. In a retrospective study of 136 acromegaly patients, treatment 
with Gamma-Knife RT caused new hormone deficiencies in 31.6% of patients 
after 8 years (Lee et al., 2014). Treatment with FSRT or LINAC in 86 acromegaly 
patients at a single institution revealed new hormone deficiencies occurring in 
19.8% of patients (Capatina & Wass, 2015; Wilson, De-Loyde, Williams, & Smee, 
2013).  
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Table 3 – Treatment Methods for Acromegaly. This table summarizes the various treatment methods that may be 
utilized to treat acromegaly. Listed are type of therapy, the parameters for biochemical control, the onset of the 
physiological response to therapy, and the result of the tumor mass (Shlomo Melmed, 2006). 
Variable Surgery Radiotherapy Somatostatin 
Receptor Ligands 
GH Receptor 
Antagonist 
DA 
 
Type of therapy 
or drug 
 
Transsphenoidal 
Resection 
 
Conventional or 
Radiosurgery 
Octreotide, Octreotide 
LAR, Lanreotide, 
Lanreotide Autogel 
 
Pegvisomant 
 
Cabergoline 
Biochemical 
Control: 
 
GH <2.5 µg/L 
 
 
 
Normalization of 
IGF-1 
 
 
 
 
Macroadenomas, 50%; 
Microadenomas, >80% 
 
 
Macroadenomas, <50%; 
Microadenomas, >80% 
 
 
 
Approximately 35% 
in 10 years 
 
 
<30% 
 
 
 
Approximately 70% 
 
 
 
Approximately 70% 
 
 
 
Level increased 
 
 
>90% 
 
 
 
<15% 
 
 
 
<15% 
 
Onset of 
Response 
 
 
Rapid 
 
Slow (years) 
 
Rapid 
 
Rapid 
 
Slow (weeks) 
 
 
Tumor Mass 
 
 
Resected or debulked 
 
 
Ablated 
 
Growth constrained 
or tumor shrunk, 
about 50% 
 
 
 
Unknown 
 
 
Unchanged 
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Combination Therapy 
Through various studies, it has been found that acromegaly is best treated 
using a combination of therapies. In most cases of acromegaly caused by a 
microadenoma or noninvasive macroadenoma, the primary treatment method is 
transsphenoidal surgery. When the tumor is completely resected and the tumor 
does not recur, biochemical remission may be achieved. In this case, the patient 
will have an annual measurement of IGF-1 levels and GH levels following an 
OGTT. In the event that the tumor is not completely resected there may be 
clinical or biochemical signs that the tumor is recurrent, and other treatment 
methods should be utilized. The next mode of treatment may either be 
reoperation, medical therapy, or RT, depending on the remaining tumor size, 
invasiveness, and location.  
For some patients, the initial tumor may be unresectable, the tumor may 
not be causing chiasmal compression, or the patient is a poor candidate for 
surgery. In these cases, medical therapy is considered as the primary 
intervention. Medical therapy includes SRLs, DAs, and Pegvisomant. In most 
cases, SRLs are the primary medical therapy of choice. If the patient only 
partially or minimally responds to SRLs, a combination therapy may be 
considered (Katznelson et al., 2014). In more recent studies, combination therapy 
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of cabergoline with SRLs was found to reduce IGF-1 levels in 52% of patients 
(Jaquet et al., 2005; Sandret, Maison, & Chanson, 2011). This may be due to the 
hetero-oligomerization of the D2 receptor and somatostatin receptor 5 (SSTR-5) 
which potentiates the individual effect of each medication (Rocheville et al., 
2000). When SRL monotherapy is not effective in reducing GH and IGF-1 levels, 
cabergoline may be added as an adjuvant therapy (Sandret et al., 2011). 
However, if the patient does not respond to medical therapy or cannot tolerate 
medical therapy, another monotherapy (surgery or SRS) should be considered. 
RT may be used at any point during medical treatment following an incomplete 
surgical resection (Figure 5) (Katznelson et al., 2014).  
 
Novel Therapies 
Novel therapies that are currently being tested for treatment of 
acromegaly are antisense drugs and botulin neurotoxin. Antisense 
oligonucleotides are short, single-stranded DNA or RNA molecules that are 
complementary to a physiologically relevant sequence. Antisense 
oligonucleotides are being constructed to block GH receptor mRNA translation 
to inhibit subsequent IGF-1 secretion (Maffezzoni, Frara, Doga, Mazziotti, & 
Giustina, 2016). In a preliminary study in the mouse model, a ten-week dosing 
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study of GH receptor antisense oligonucleotide showed a 59% decrease in 
circulating IGF-1 levels suggesting that antisense oligonucleotides are a viable 
approach to modulation of IGF-1 secretion (Tachas et al., 2006). Human clinical 
trials are currently being conducted for analysis of antisense oligonucleotide 
treatment in acromegalic patients (Maffezzoni et al., 2016). 
Another novel therapy for acromegaly that is undergoing testing is 
botulin neurotoxin. Botulin neurotoxins are endopeptidases that disrupt 
exocytosis in cells by cleaving N-ethylmaleimide-sensitive fusion attachment 
protein receptor (SNARE), a necessary protein in vesicular secretion. Engineered 
forms of botulin neurotoxins are currently being manipulated to target 
somatotrophs to decrease GH secretion. SXN101959, a targeted secretion 
inhibitor, has been found to selectively bind to GHRH receptors on 
somatotrophs. SXN101959 enters the cell and inhibits GH secretion by cleaving 
necessary SNARE proteins for exocytosis (Maffezzoni et al., 2016). In a 
preliminary investigation, the effects of SXN101959 were compared to 
administration of octreotide in male rats. SXN101959 was found to strongly 
decrease levels of GH mRNA and GH secretion in comparison to octreotide 
suggesting that SXN101959 could be applied as a novel therapeutic approach for 
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treatment of acromegaly. However, more testing is required prior to human trials 
(Somm et al., 2013). 
Studies in PAs revealed varying levels of immune cell infiltrates that 
correlate to tumor size and invasiveness. There is a greater infiltration of CD68+ 
macrophages in adenomas that are larger in size and more invasive. GH-
secreting PAs also have more infiltration of CD4+ T cells and CD8+ cytotoxic T 
cells in comparison to non-GH-secreting PAs. This data suggests that a better 
understanding of the immune cell microenvironment may provide insight into 
development of immunotherapies that can be utilized to target PA growth and 
invasiveness (Lu et al., 2015). In a case report, a 27-year-old patient presented 
with a large, aggressive, GH and PRL secreting PA. Immunohistochemistry of 
the tissue revealed programmed death ligand 1 (PD-1) expression and CD8+ 
cytotoxic T cell infiltration. There is speculation that inhibition of programmed 
cell death protein 1 could assist CD8+ cytotoxic T cells identify and kill tumor 
cells. This infiltration of immune cells suggests the existence of an immune 
response to PAs. Therefore, immune checkpoint inhibitors such as, anti-PD-1, 
could serve as an effective immunotherapy for acromegaly patients (Wang et al., 
2017).  
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Gene Therapies 
Gene therapy utilizes recombinant viral vectors to deliver therapeutic 
genes to target organs or tissues. Most studies investigate the efficacy of 
adenovirus-derived vectors due to their ability to infect a wide variety of cells 
and their high efficiency in gene transfer in dividing and non-dividing cells 
(Rodriguez, Castro, Brown, Goya, & Console, 2009). Preliminary studies in 
normal and neoplastic rat anterior pituitary revealed that adenovirus-derived 
vectors transfer different genes more efficiently in neoplastic rat anterior 
pituitary cells than normal rat anterior pituitary cells (Castro et al., 1997). In a 
more recent study, bioactive peptide gene delivery of IGF-1 was implemented in 
rats with estrogen-induced prolactinomas. Upon administration of IGF-1 gene 
therapy, there was a significant decrease in lactotroph size and density along 
with serum PRL levels (Console et al., 2008). In another study, IGF-1 gene 
therapy normalized somatotroph cell density and reduced GH secretion in 
female rats (Cónsole et al., 2009). However, due to the high likelihood of an 
inflammatory response to adenoviruses, more research is required to test the 
safety of this treatment method. In contrast, another study investigated the 
efficiency of lentiviral vectors, such as the human immunodeficiency virus, as a 
vehicle of gene transfer to GH secreting pituitary adenomas. The study revealed 
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an effective transduction of genes for up to a three-month period, suggesting 
lentiviral vectors may be utilized in gene therapy (Roche et al., 2019). Gene 
therapy has high applicability in the treatment of pituitary tumors, however, the 
research is preliminary and has not been applied to human models. For this 
reason, there is also a lack of evidence of side effects that may present upon gene 
therapy administration. There is a high likelihood of an immune response that 
may be elicited due to viral exposure, especially if re-administration of therapy is 
required (Castro, Southgate, & Lowenstein, 2001).  
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Figure 5 – Treatment Outline for Acromegaly. This is a proposed outline for treatment of acromegaly (Katznelson 
et al., 2014). 
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DISCUSSION 
 
 Acromegaly is a complex condition caused by a benign PA that leads to 
elevated serum GH levels. GH causes subsequent release of IGF-1 from 
peripheral tissue leading to the clinical manifestations of acromegaly. There are 
currently three therapies for acromegaly including medical therapy, RT, and 
surgery. The goals of acromegaly treatment are to reduce GH levels and IGF-1 
levels to age/sex-normalized levels, relieve comorbidities, normalize mortality 
rate, and to remove the pituitary mass causing high hormone levels. Prior to 
deciding what therapy is appropriate for treatment of acromegaly, a thorough 
analysis must be conducted of the patient’s IGF-1 and GH levels, tumor size, 
tumor invasiveness, MRI or CT scans, compressive side effects of the tumor, and 
comorbidities.  
Currently, surgery is the primary choice of treatment for GH-secreting 
PAs. Surgery is highly effective at achieving remission in patients with 
microadenomas and noninvasive macroadenomas. It is a relatively low-cost 
treatment method that has a high success rate (Table 4). According to data from 
2008, the median cost of transsphenoidal surgery in the United States was 
estimated at $39,311 which is much less than the lifetime cost of long-term RT or 
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medical therapy (Marko et al., 2012). However, surgical resection is not an 
effective treatment method for patients with large macroadenomas that invade 
important neurovascular structures. The size and location of the tumor pose as 
major limitations when attempting a total resection. In some cases, not all of the 
PA can be safely resected, therefore, a residual portion may be left behind. 
Subsequently, there is persistent GH hypersecretion from the remaining tumor. 
Surgical debulking of the tumor mass increases the efficacy of medical therapies 
and SRS in obtaining biochemical control by decreasing the volume of the tumor.  
SRS and FSRT are not generally used as the first line of therapy due to the 
detrimental side effects and costs of potential subsequent therapy sessions. It is 
commonly used after surgical resection in cases where the PA cannot be 
completely resected. SRS may also be used after medical therapies if clinically 
available drugs are not able to reduce IGF-1 and GH to age/sex-normalized levels 
or are not well-tolerated by the patient. However, there are many disadvantages 
to SRS including hypopituitarism, radio-necrosis of normal brain tissue, and 
secondary tumor formation. SRS may have a long latency period of up to 10 
years for patients to achieve remission, therefore, patients require therapy for 
long periods of time. Although, treatment with SRL during the SRS latency 
period may assist in managing IGF-1 and GH levels. The average cost of SRS is 
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$56,356 which is slightly more than surgery (Table 4) (Zygourakis et al., 2017). 
Despite these issues, SRS is an effective method at reducing tumor size and 
gaining biochemical control in acromegaly patients.  
DAs are also another commonly suggested treatment for management of 
acromegaly. They are available at a relatively low cost and are available as an 
oral therapy which is much less invasive than surgery (Kumar et al., 2009). 
According to data from 2010 through 2015 in California, the approximate lifetime 
cost of cabergoline treatment is $70,696 (Table 4) (Zygourakis et al., 2017). 
However, DAs are not as effective as other medical therapies or surgery since 
they only decrease IGF-1 and GH levels in patients with mild elevations and do 
not decrease tumor volume. DAs may also have adverse effects that decrease 
patient compliance. 
In comparison to DAs, SRLs are a more expensive medical treatment with 
a lifetime cost of approximately $1,622,597 according to data from 2008 (Table 4)  
(Marko et al., 2012). SRLs appear to be effective at reducing and managing IGF-1 
levels and GH levels as well as tumor shrinkage in some cases. Studies have also 
reported use of SRLs prior to surgical resection to improve surgical resection, 
reduce comorbidities, and reduce surgical complications. SRLs may also be used 
in conjunction with cabergoline to reduce IGF-1 levels that are resistant to SRL 
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monotherapy. The main disadvantage of SRLs is the side effect of hyperglycemia 
which poses many issues for patients already experiencing many comorbidities. 
The final medical therapy utilized for management of acromegaly is 
Pegvisomant. Among clinically available therapies for acromegaly, Pegvisomant 
is the most expensive with an approximate lifetime cost of $2,325,423 as reported 
in 2008 (Table 4) (Marko et al., 2012). Although, in comparison to SRLs and DAs, 
Pegvisomant is also the most effective medical therapy in managing IGF-1 levels. 
Pegvisomant does not have any anti-tumor growth effects, rather, the tumor may 
proceed to grow while patients are on this treatment regimen. The greatest 
disadvantage of Pegvisomant is the possibility of irreversible liver damage that 
elevates liver enzymes in patients.  
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Table 4 – Summary of Treatment Cost, Efficacy, and Side Effects. Surgery is the 
least expensive treatment method among SRS, cabergoline, SRLs, and 
Pegvisomant. However, it should be noted that in some cases, reoperation is a 
necessary means of treating acromegaly as are combination therapies (Marko et 
al., 2012; Zygourakis et al., 2017). 
 
Treatment Cost (lifetime) Side Effects 
Surgery $39,311 
Rare (meningitis, 
CSF leak) 
SRS $56,356 Hypopituitarism 
Cabergoline $70,696 
Common (nausea, 
headache, 
dizziness) 
SRLs $1,622,597 
Common 
(abdominal pain, 
hyperglycemia) 
Pegvisomant $2,325,423 
Common (elevated 
liver enzymes) 
 
There are various studies that present novel therapies for treatment of 
acromegaly that are currently being tested in animal and human models. These 
include antisense drugs, modified botulin neurotoxins, and immunotherapies. 
Although studies suggest these novel therapies may be successful treatment in 
acromegaly, data is limited and more analysis is necessary prior to human trials. 
An emerging treatment method for pituitary tumors is gene therapy. 
Various studies in animal models revealed the efficacy of adenoviruses and 
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lentiviruses as vehicles for gene transfer. These studies are preliminary and 
provide limited information in regards to the potential side effects of gene 
therapy. Further research is necessary prior to application in human clinical 
trials. Despite the hazards associated with gene therapy, proper manipulation of 
viral immunogenic effects could prove gene therapy as a more successful 
treatment for large macroadenomas, invasive PAs, and recurrent PAs. Injection 
of vectors into sites of residual tumor may eradicate the tumor entirely. In cases 
where a total surgical resection of a recurrent PA is performed, patients may 
have vectors injected into the normal brain parenchyma to prevent regrowth of 
the PA. In some cases, patients are not able to tolerate medical therapies due to 
adverse effects and permanent complications such as diabetes insipidus. Gene 
therapy may prove as an effective alternative for these patients. However, 
improvements for existing gene therapy vectors are necessary and they include 
an increase in efficiency of the vector so lower doses may be administered, a 
decrease in immunogenicity so re-administrations are possible, an increase in the 
levels and duration of transgene expression, and an increase in the transduction 
area (Castro et al., 2001). 
In conclusion, the primary treatment method for acromegaly is surgery 
due to its limited complications, low cost, and remission in the majority of cases. 
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Medical therapies are successful at attaining biochemical control of acromegaly, 
but they do not effectively decrease tumor volume in all patients and are 
expensive in comparison to SRS and surgery. Medical therapy may be utilized in 
patients that cannot undergo surgery or patients that require secondary 
treatment after incomplete tumor resection. Pegvisomant appears to be the most 
effective medical therapy at gaining biochemical control in patients. However, 
the permanent side effects and cost of medical therapies prevent its applicability 
to all patients. SRS is also an effective treatment method for patients that cannot 
undergo surgery or have residual unresectable tumor after surgery. However, 
the long latency period hinders SRS from being effective in immediately 
reducing IGF-1 and GH levels. For this reason, SRS in combination with SRLs 
may be more affective at managing and treating acromegaly. Despite the success 
of current treatment methods, therapeutic alternatives must be explored to treat 
invasive macroadenomas and recurrent PAs. Future research may provide 
greater insight into the development of new immunotherapies and molecular 
therapies that may prove as more effective and less invasive treatment methods 
for acromegaly.	  
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